구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 178 trials·t½ 4 h |
|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine / T-DM1) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ breast cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Stable linker, DAR ~3.5 |
Positioning Known limitation | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). |
Positioning Development positioning | Established SOC before Enhertu head-to-head |
Technology Payload | MMAE (maytansinoid) |
Technology Linker | Non-cleavable SMCC |
MoA Mechanism | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. |
MoA Biomarker | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). |
PK/PD Half-life | 4 h |
PK/PD Species | Mouse, Tumor response |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity |
Toxicology CRS | Minimal |
Clinical Safety signal | Thrombocytopenia, hepatotoxicity |
Clinical Selected reported efficacy | ORR 43.6% |
Clinical Reported ORR | 43.6% (EMILIA) |
Clinical Reported PFS | 9.6 mo |
Clinical Reported OS | 30.9 mo |
Clinical Result source | EMILIA |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | EMILIA |
Preclinical Animal (cat.) | In vitro |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 178 trials·t½ 4 h |
|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine / T-DM1) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ breast cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Stable linker, DAR ~3.5 |
Positioning Known limitation | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). |
Positioning Development positioning | Established SOC before Enhertu head-to-head |
Technology Payload | MMAE (maytansinoid) |
Technology Linker | Non-cleavable SMCC |
MoA Mechanism | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. |
MoA Biomarker | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). |
PK/PD Half-life | 4 h |
PK/PD Species | Mouse, Tumor response |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity |
Toxicology CRS | Minimal |
Clinical Safety signal | Thrombocytopenia, hepatotoxicity |
Clinical Selected reported efficacy | ORR 43.6% |
Clinical Reported ORR | 43.6% (EMILIA) |
Clinical Reported PFS | 9.6 mo |
Clinical Reported OS | 30.9 mo |
Clinical Result source | EMILIA |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | EMILIA |
Preclinical Animal (cat.) | In vitro |
추천 비교
추천 비교